Triamcinolone Eye Injection 40 mg - TGA Unlicensed Products
HL Pharma has exclusive distribution rights for numerous products and also specialises in sourcing and supply of products that are unlicensed in Australia.
These products may not have TGA registration or maybe an Australian product with supply issues. They are usually supplied under The Special Access Scheme (SAS) or Authorised Prescriber Scheme (APS). Other pathways to supply include Clinical Trial Supply.
For further information on sourcing Triamcinolone Eye Injection 40 mg and other brands such as; Intracinol® & Triesence® see below, or for further information on sourcing this product or any others, please don't hesitate to contact us.
Triamcinolone Preservative Free Eye Injection 40 mg
What is Triamcinolone 40mg/ml Intraocular preservative-free eye injection?
Triamcinolone has been used as an injection into the eye for a few years now to control the swelling of the retina (macular oedema) in diabetic retinopathy (retina affected by diabetes), vascular occlusions (blockage of veins of the retina) and in other conditions including age-related macular degeneration.
Triamcinolone 40mg/ml intraocular eye injection, is a preservative-free solution used for the treatment of non-infectious uveitis, diabetic macular oedema, cystoid macular oedema secondary to retinal vein occlusion, uveitic macular oedema and postoperative macular oedema.
It's a long-acting steroid and its effect may last for three to six months.
There are no TGA licensed Triamcinolone injections for intraocular use in Australia.
Supply of Ophthalmic Triamcinolone Injection Australia
Triamcinolone intraocular eye injection is licensed in a number of countries including The United Kingdom, USA, Canada, and various countries of Europe. Brands include Intracinol® and Triesence®. The Australian product Kenacort A40® is not licensed for Intraocular use.
The supply of unlicensed medicine from overseas for use in Australia is often done by The Special Access Scheme.
Ophthalmic Triamcinolone 40mg/ml intraocular injection is often supplied under Special Access Scheme (SAS) C for treatment for:
- Non-infectious uveitis
- Diabetic macular oedema
- Cystoid macular oedema secondary to retinal vein occlusion
- Uveitic macular oedema
- Postoperative macular oedema
The SAS C system just requires the prescriber to notify The Therapeutic Goods Administration (TGA) of the use.
If a prescriber requires many patients to use Triamcinolone 40mg/ml Intraocular eye injection (Preservative Free), or other brands including Intracinol® and Triesence® they can apply for an Authorised Prescriber approval.